Phase II Study of Gemcitabine and Docetaxel Combination in Patients with Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Table 1

Phase II studies of biweekly gemcitabine and docetaxel (GEMDOC).

Author	𝑁	Tumor type	Treatment regimen	Toxicity
Galetta et al. [11]	45	NSCLC	Gemcitabine 2000 mg/m^2 q 2 weeks and docetaxel 50 mg/m^2	Grade 3 and 4 neutropenia 23%, Grade 3 and 4 alopecia 34%
Pelegri et al. [12]	36	Breast cancer	Gemcitabine 2500 mg/m^2 q 2 weeks and docetaxel 65 mg/m^2	Grade 3 and 4 neutropenia 45%
Syrigos et al. [13]	25	NSCLC	Gemcitabine 1000 mg/m^2 q 2 weeks and docetaxel 80 mg/m^2	Anemia 16%, neutropenia 20%, febrile neutropenia 10%, diarrhea 24%, and asthenia 64%
Shepard et al. [14]	32	Pancreatic	Gemcitabine 2000 mg/m^2 q 2 weeks and docetaxel 75 mg/m^2	No grade 4 toxicity; Grade 3 neutropenia 31%